

ATTENTION ON ADHD: THE VALUE OF IMPROVING CARE FOR PEOPLE WITH ADHD SNAPSHOT



Norway

Overview of the ADHD Landscape in Norway

COUNTRY	CONTEXT	DISEASE BURDEN/EP	IDEMIOLOGY	\$ P	ADHD RESEARCH
Population 5,435,639 ¹		ADHD prevalence rate for adults (18-65) 2.5% ⁵ (84,688 patients) ⁶ **		Number of clinical trials 2 ⁷ (from 01.08.12 to 01.08.22)	
				ል ^ሴ ል ል ል ሴ _ሴ ሴ	EUROPEAN ORGANISATION
Current health expenditure (% of GDP)	10.52%²	P	REGISTRIES	ADHD Europe	ADHD EUROPE CREATING AWARENESS OF AD/HD
		Is there a ADHD registry in the country?	NO		
Domestic general government health expenditure (% of GDP)				愛	NATIONAL ORGANISATION
- Hearth experience (70 of obr		REFERENCE CENTRES		ADHD Norge	
Out-of-pocket expenditure (%)	(%) 13.864	Number of reference centres	NO INFO	¥ <u>=</u>	NATIONAL GUIDELINES
		/ centres of excellence		National guideline?	NO

- 1 World Population in Review. Norway Population (estimate on 31 August) Available at: https://worldpopulationreview.com/countries/norway-population Last accessed October 2022.
- ² The World Bank. Current Health expenditure (% of GDP) Norway. Available at: https://data.worldbank.org/indicator/SH.XPD.CHEX.GD.ZS?locations=NO Last accessed October 2022.
- The World Bank. Domestic general government health expenditure (% of GDP) Norway. Available at: https://data.worldbank.org/indicator/SH.XPD.GHED.GD.ZS?locations=NO Last accessed October 2022.
- 4 The World Bank. Out-of-pocket expenditure (% of current health expenditure) Norway. Available at: https://data.worldbank.org/indicator/SH.XPD.OOPC.CH.ZS?locations=NO Last accessed October 2022.
- ⁵ Faraone S V., Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, et al. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021 Sep 1;128:789-818.
- ⁶ Statistics Norway. Population Statistics [Internet]. 2022 [cited 2022 Jul 1]. Available from: https://www.ssb.no/en/befolkning/folketall/statistikk/befolkning
- ⁷ EU Clinical Trials Register. Last accessed November 2022. Available at: https://www.clinicaltrialsregister.eu/

^{*}Treating to 70% of the estimated prevalence of patients means increasing rates of diagnosis meaning that the percentage of patients increases by 30% from 40-70 leading to a higher number of patients being treated in the health system).

**Adult patient population is calculated by multiplying the ADHD prevalence rate from Faraone et al, 2021 by the country's 18-65 population data (see endnotes).